| Unsubscribe |
Editor’s Note: Jeff Brown is the former tech executive who picked Nvidia in 2016 before it jumped 37,000% higher. He’s now recommending another AI stock that’s the same size Nvidia was 10 years ago. He calls it “Elon Musk’s One Stock Retirement Plan” because he believes Elon Musk is about to create massive demand for this company’s patented technology. Click here to see the details or read more below.
Dear Reader,
Sometimes you come across an opportunity so explosive…
That it has the potential to turn a small stake…
Into a six figure and in some rare cases even a seven-figure nest egg…
Like it happened when I picked Nvidia in 2016.
It jumped high enough to turn $5,000 into an entire retirement nest egg of $1,895,000.
And while I can’t guarantee you’ll become a millionaire...
I think this little-known AI stock is one of those opportunities…
Which is why I call it “Elon Musk’s One Stock Retirement Plan.”
Now, if this idea of retiring with a single stock sounds crazy to you…
You should know that some of the best investors in the world believe that the idea of diversification is a little overrated.
Stanley Druckenmiller said…
“You don’t get rich by diversifying into 50 mediocre assets. You get rich by finding two or three asymmetric home runs.”
I believe this stock is an asymmetric home run.
Or listen to legendary investor Peter Lynch. He said…
“I would own one stock if I can find one great stock.”
Even Warren Buffett said…
“Diversification is protection against ignorance. It makes little sense if you know what you are doing.”
Click here now and I’ll show you why I believe this stock might be the only one you need to retire.
Jeff Brown,
Founder & CEO, Brownstone Research
P.S. If I could buy only one stock, this would be it… it might just be the perfect tech stock.
It’s a leader in an AI breakthrough that’s protected by 150 patents…
It’s a small company, unknown to most people… still in the initial phase of exponential growth…
Plus, it has a near term catalyst that could send shares skyrocketing… starting November 11.
Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
Author: Ryan Hasson. Article Posted: 10/21/2026.
Key Points
- Biotech and pharmaceutical stocks have shown relative strength and held near highs even as the technology and AI trade sold off sharply.
- The iShares Biotechnology ETF is up almost 21% year-to-date, reflecting gains across both defensive pharma giants and growth-oriented biotech innovators.
- Eli Lilly and Pfizer stand out within the sector, with Lilly leading on GLP-1 drug growth and Pfizer offering a cheap valuation plus high dividend yield.
- Special Report: Grand Canyon Discovery Reshapes America's Energy Tax Credits.
While attention has focused on the brutal sell-off tearing through the technology sector and the AI trade, something notable has been happening in another corner of the market. The biotech and pharmaceutical sector has held its ground and, relatively speaking, done so impressively.
As the Nasdaq-100 and high-flying AI names have been clobbered in recent sessions, healthcare stocks—particularly biotech and pharmaceutical names—have refused to break down. That kind of relative strength amid a broad risk-off move is exactly what is worth paying attention to.
Nvidia's Huang doubts Musk's latest mega plan can work (Ad)
Nvidia CEO Jensen Huang says Elon Musk's $119 billion plan will be extremely hard to pull off.
Larry Benedict, who ran a $900 million hedge fund and posted 20 consecutive years without a loss, including over $274 million in audited net income between 2004 and 2012, says one long forgotten American company already holds what Musk needs.
Get the ticker and his full analysis before the November 30 deadline.
Click here to get the free ticker before November 30One of the clearest ways to track the sector is the iShares Biotechnology ETF (NASDAQ: IBB), which holds a broad basket spanning high-growth biotech innovators and large, established pharmaceutical companies.
The fund is up almost 21% year to date and continues to trade near the top of its range, even as tech has rolled over.
Why Biotech and Pharma Are Attracting Attention
So why is the space holding up? It helps to separate two groups that are often lumped together. True biotech—the smaller, innovation-driven companies pursuing breakthroughs and clinical milestones—is a genuine growth space that is speculative and volatile by nature. Large, established pharmaceutical companies are a different animal: Proven drugs, mature pipelines, and steady, recurring revenue make them defensive businesses. People need their medicines regardless of the economy or stock market, giving pharma giants dependable and far less cyclical cash flows.
Both groups have reasons to be attracting investor interest. Established pharma heavyweights offer the stability that capital seeks as it flees stretched valuations in the AI trade. The biotech side, meanwhile, has its own tailwinds, including a pickup in acquisition activity across the sector, improving sentiment, and growing excitement around AI-driven efficiency and breakthrough potential in drug discovery. One side brings defensive stability, while the other brings innovation and upside—and both are working right now.
Identifying relative strength is one thing, but the more interesting question is what comes next. If the broader market finds its footing while the sector continues to hold firm, it could be well positioned to outperform on the next leg higher. With that in mind, here are two individual names worth watching that stand out for their recent relative strength and outperformance.
Eli Lilly: The Growth Engine Near Its Highs
Eli Lilly (NYSE: LLY) is the pharma giant leading the pack. The stock is up almost 16% year to date and trades within roughly 4% of its 52-week high, displaying notable relative strength as the broader market wobbles. More importantly, it has been consolidating tightly near those highs, suggesting the potential for a bullish breakout. Lilly's run is driven by its dominance in the booming GLP-1 obesity and diabetes market, led by Mounjaro and Zepbound, which has driven projected earnings growth north of 40%.
Despite that growth, Lilly behaves defensively, with a beta of just 0.46. Analysts rate it a Moderate Buy, with an average price target of $1,313.43. The stock is not cheap, with a forward price-to-earnings ratio of around 37, but that premium reflects its status as one of the fastest-growing large caps in healthcare—and one that is holding up far better than most of the market right now.
Pfizer: The Value-and-Income Turnaround
Pfizer (NYSE: PFE) offers a very different profile and has quietly been one of the sector's standout performers this year. The stock is up more than 18% year to date and sits less than 2% from its 52-week high. It has firmly held above prior resistance, which now acts as newfound support, as it approaches a breakout from a tight consolidation. After several sluggish years following its pandemic-era boom, Pfizer is showing real signs of life and leadership.
What makes Pfizer compelling here is its blend of deep value and income. The stock trades at a rock-bottom forward price-to-earnings (P/E) ratio of around 10 and pays a hefty 5.84% dividend. Analysts rate it a Hold, a reminder that the turnaround still has plenty to prove. However, its cheap valuation, substantial yield, and genuine price momentum have made it a magnet for investors seeking safety with upside.
Strength Worth Watching
The sector's relative strength is a genuine standout in an otherwise turbulent market. IBB offers exposure to the theme, while Eli Lilly and Pfizer represent two very different ways to play it: one is a high-growth leader pressing against its highs, while the other is a cheap, high-yielding turnaround.
The real test will come if and when the broader market stabilizes. If the group holds firm through the turbulence, it could lead when—and if—the bull market resumes. For now, it is one of the few corners of the market quietly refusing to break.
3 Companies With Room to Pass on Costs to Manage Inflation
Written by Nathan Reiff. Date Posted: 10/26/2026.
Key Points
- Rising inflation in September 2026 pushed up costs for many companies, though some have pricing power to offset the impact.
- WD-40 and Balchem both posted strong sales and earnings growth despite margin pressure, supported by premium and innovative product demand.
- Interparfums faces shrinking operating margins from higher costs but may benefit from loyal luxury customers willing to pay premium prices.
- Special Report: Grand Canyon Discovery Reshapes America's Energy Tax Credits.
Despite the Federal Reserve's decision to raise interest rates in September 2026, inflation accelerated again that month, with the Consumer Price Index rising 0.6%, compared with 0.4% in August. Not all goods—and, therefore, not all companies—will experience the same impact. Energy and gasoline prices have been among the fastest to rise, and the essential nature of these products means that many companies face higher costs even if their own prices have not increased at the same pace.
A natural response for a company in this situation is to raise the prices of its offerings to offset some or all of those added costs. However, after an already prolonged period of inflation, consumers are highly sensitive to further price increases. Still, some companies may have more flexibility to pass costs along to customers, either because of the essential or unique nature of their products, the loyalty of their customer base, or the fact that their prices have not yet risen as quickly as those of competitors.
WD-40 Leads With Specialized Products That Command Premium Pricing
NNVC Advances NV-387 Into Phase II Trials for Ebola and Mpox (Ad)
NanoViricides, Inc. (NYSE American: NNVC) is advancing NV-387, a broad-spectrum antiviral candidate, into Phase II trials for both Ebola and Mpox.
The Ebola outbreak in the Democratic Republic of Congo continues to expand, with thousands of confirmed deaths already reported. NV-387 targets a host-side feature viruses rely on rather than a rapidly mutating viral target, and the company is also planning clinical development for measles.
See why NV-387 could become a closely watched antiviral candidate.Known for its popular water-displacing spray and lubricant of the same name, the WD-40 Company (NASDAQ: WDFC) provides a range of products for specialized maintenance and cleaning applications. According to its latest earnings report, WD-40 experienced a decline in fourth-quarter gross margin because of rising raw material costs, adding pressure to its margin outlook.
At the same time, the company's sales volumes have remained robust, both domestically and abroad. Last quarter, WD-40 Specialist sales in the Americas climbed 7% year over year (YOY), while consolidated net sales increased 8% over the same period. Some of this success may stem from the company's efforts to develop differentiated, premium products tailored to specific customer needs.
This combination of sales momentum, brand recognition, and niche products that address proven customer needs gives WD-40 the flexibility to adjust pricing and help offset the margin pressure it has experienced. In particular, the firm's premium Smart Straw and EZ Reach products posted combined sales growth of 17% year over year in fiscal 2026.
Analysts remain generally favorable toward WDFC shares, with a consensus rating of Moderate Buy. MarketBeat's consensus price target suggests approximately 45% potential upside, even after the stock's gains this year. WD-40's accelerating share buybacks could provide additional support for long-term investors.
Balchem's In-Demand Products Generate Robust Results Across Multiple Fronts
Balchem Corp. (NASDAQ: BCPC) makes specialty nutrients for use in dietary supplements, pharmaceuticals, and food and beverage applications, among other products. In its Q3 2026 earnings report, the company demonstrated resilience despite inflation, reporting a 9% YOY increase in net sales and a 16% improvement in net earnings over the same period. Both results exceeded analyst expectations.
For Balchem, continued success stems in part from its evolving product lineup, including a pipeline of innovative nutrition products backed by strong demand. All three of the company's reporting segments achieved YOY growth during the quarter, indicating that its business remains stable despite rising costs.
One area that may be less appealing to income-focused investors is the firm's dividend, which offers a relatively modest yield of approximately 0.55%. At the same time, Balchem has repurchased $127 million in shares over the last year, demonstrating that the company remains focused on ways to boost shareholder value.
Analysts view BCPC shares favorably, with a large majority rating the stock a Buy and setting a consensus price target 14% above current trading levels, even after shares have already risen by more than 14% year to date.
Interparfums Capitalizes on Luxury Cache
A provider of fragrances and beauty products, Interparfums Inc. (NASDAQ: IPAR) holds licensing agreements with a variety of international luxury brands. Like the companies above, Interparfums has faced pressure from increased expenses, including those related to marketing, logistics, tariffs, and royalties. Operating margin fell to 17.9% from 20% during the first half of 2026.
Some luxury brands have bucked the broader retail trend, continuing to attract interest and, in some cases, seeing rising demand and sales as loyal customers remain willing to pay more for products they recognize and trust.
Interparfums may benefit from that dynamic, with an additional buffer provided by the fact that its customers are not individual consumers but rather high-end department stores, online retailers, and specialty perfume and beauty stores.
Interparfums is also working to offset costs through other measures, including cost-efficiency initiatives, pricing adjustments, and tariff refunds.
This message is a sponsored message from Brownstone Research, a third-party advertiser of The Early Bird and MarketBeat.
If you need help with your account, please contact MarketBeat's support team, based in the United States, at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 North Reid Place #620, Sioux Falls, SD 57103. United States..
